Abcellera Biologics Inc (ABCL)vsEli Lilly and Company (LLY)
ABCL
Abcellera Biologics Inc
$11.88
+6.74%
HEALTHCARE · Cap: $3.98B
LLY
Eli Lilly and Company
$1,354.49
-0.79%
HEALTHCARE · Cap: $1.26T
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 130566% more annual revenue ($86.46B vs $66.17M). LLY leads profitability with a 31.9% profit margin vs -248.8%. LLY earns a higher WallStSmart Score of 74/100 (B).
ABCL
Avoid27
out of 100
Grade: F
LLY
Strong Buy74
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+54.9%
Fair Value
$6.94
Current Price
$11.88
$4.94 discount
Intrinsic value data unavailable for LLY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Earnings expanding 45.9% YoY
Mega-cap, among the largest globally
Every $100 of equity generates 68 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 53.7%
Revenue surging 38.6% year-over-year
Generating 8.2B in free cash flow
Areas to Watch
Distress zone — elevated risk
ROE of -15.3% — below average capital efficiency
Revenue declined 76.3%
Negative free cash flow — burning cash
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 30.0x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ABCL
The strongest argument for ABCL centers on Debt/Equity, EPS Growth.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.9% and operating margin at 53.7%. Revenue growth of 38.6% demonstrates continued momentum.
Bear Case : ABCL
The primary concerns for ABCL are Altman Z-Score, Return on Equity, Revenue Growth.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 46.0x leaves little room for execution misses.
Key Dynamics to Monitor
ABCL profiles as a turnaround stock while LLY is a growth play — different risk/reward profiles.
ABCL carries more volatility with a beta of 1.41 — expect wider price swings.
LLY is growing revenue faster at 38.6% — sustainability is the question.
LLY generates stronger free cash flow (8.2B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (74/100 vs 27/100), backed by strong 31.9% margins and 38.6% revenue growth. ABCL offers better value entry with a 54.9% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abcellera Biologics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
AbCellera Biologics Inc. develops an antibody discovery platform. The company is headquartered in Vancouver, Canada.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?